ERBB2 and breast carcinoma: The trials compare the use of multigene tests with the clinical practice, evaluating the adjuvant chemotherapy in patients with early breast cancer (stage I, II or III operable) with 0–3 positives nodes, ER+ (and/or PgR-positive) and HER2-.